Most experience exists for sitagliptin (Merck) and vildagliptin (Novartis), which both have a long duration of action, allowing once-daily administration. In drug-naïve subjects with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback